Mineralys Therapeutics, Inc. (MLYS)
20.93
+0.63
(+3.10%)
USD |
NASDAQ |
Oct 19, 15:49
Mineralys Therapeutics Net Income (Quarterly) : -241.07M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -241.07M |
| March 31, 2026 | -39.34M |
| December 31, 2025 | -32.23M |
| September 30, 2025 | -36.93M |
| June 30, 2025 | -43.27M |
| March 31, 2025 | -42.21M |
| December 31, 2024 | -48.95M |
| September 30, 2024 | -56.34M |
| June 30, 2024 | -41.01M |
| March 31, 2024 | -31.51M |
| Date | Value |
|---|---|
| December 31, 2023 | -24.39M |
| September 30, 2023 | -22.76M |
| June 30, 2023 | -12.14M |
| March 31, 2023 | -12.61M |
| December 31, 2022 | -9.073M |
| September 30, 2022 | -6.678M |
| June 30, 2022 | -6.479M |
| March 31, 2022 | -7.569M |
| December 31, 2021 | -7.083M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 241.07M |
| EPS Diluted (Quarterly) | -2.845 |
| Enterprise Value | 1.230B |
| Earnings Yield | -20.28% |
| Normalized Earnings Yield | -20.27 |